{"product_id":"abcam-ab271111","title":"Abcam, ab271111, Anti-VAChT antibody [EPR24248-167]","description":"\u003cp\u003eSize: 20µL \/ 100µL \/ 1mL\u003cbr\u003e\nRabbit Recombinant Monoclonal VACHT antibody. Suitable for IP, IHC-P and reacts with Mouse, Rat samples.\u003cbr\u003e\nKey facts\u003cbr\u003e\nHost species:Rabbit,\u003cbr\u003e\nClonality:Monoclonal,\u003cbr\u003e\nClone number:EPR24248-167,\u003cbr\u003e\nIsotype:IgG,\u003cbr\u003e\nCarrier free:No,\u003cbr\u003e\nReacts with:Mouse, Rat,\u003cbr\u003e\nApplications:IP, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,\u003cbr\u003e\nImmunogen:The exact immunogen used to generate this antibody is proprietary information.\u003c\/p\u003e\n\n\u003cp\u003eProduct details:\u003cbr\u003e\nPatented technology\u003cbr\u003e\nOur RabMAb\u003cbr\u003e\ntechnology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to\u003cbr\u003e\nRabMAb® patents\u003cbr\u003e\nWhat are the advantages of a recombinant monoclonal antibody?\u003cbr\u003e\nThis product is a recombinant monoclonal antibody, which offers several advantages including:\u003cbr\u003e\n- High batch-to-batch consistency and reproducibility\u003cbr\u003e\n- Improved sensitivity and specificity\u003cbr\u003e\n- Long-term security of supply\u003cbr\u003e\n- Animal-free batch production\u003cbr\u003e\nFor more information, read more on\u003cbr\u003e\nrecombinant antibodies\u003c\/p\u003e\n\n\u003cp\u003eProperties and Storage Information:\u003cbr\u003e\nForm-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze \/ thaw cycle\u003c\/p\u003e\n\n\u003cp\u003eSupplementary Information:\u003cbr\u003e\nThis supplementary information is collated from multiple sources and compiled automatically.\u003cbr\u003e\nThe vesicular acetylcholine transporter often referred to as VAChT is responsible for packaging acetylcholine into vesicles in cholinergic neurons. This process is important for synaptic transmission in the nervous system. VAChT functions by using a proton gradient to transport acetylcholine against its concentration gradient into synaptic vesicles. VAChT has a molecular mass of approximately 55 kDa. It is widely expressed in cholinergic neurons throughout the central and peripheral nervous systems particularly in regions such as the cortex hippocampus and neuromuscular junctions.\u003cbr\u003e\nBiological function summary\u003cbr\u003e\nThe function of VAChT plays an important role in the cholinergic system by facilitating neurotransmitter storage essential for neural communication. As part of the vesicular neurotransmitter transporter family VAChT collectively works with other proteins within this complex system to regulate acetylcholine availability and release. The stored acetylcholine within vesicles is released into the synaptic cleft in response to neuronal signals which promotes synapse firing and communication between neurons.\u003cbr\u003e\nPathways\u003cbr\u003e\nAcetylcholine packaging and release managed by VAChT is integral to the cholinergic signaling pathway. This pathway is fundamental to ensuring proper function of learning memory and muscle control processes. VAChT works closely with the protein choline acetyltransferase (ChAT) which synthesizes acetylcholine from choline and acetyl-CoA. These proteins ensure a seamless conversion and transport loop within cholinergic neurons to maintain efficient neural signaling.\u003cbr\u003e\nVAChT has been linked to conditions that involve impaired cholinergic function such as Alzheimer's disease and myasthenia gravis. In Alzheimer's disease disruptions in the cholinergic system often marked by reduced VAChT expression contribute to cognitive decline. VAChT variations can also impact acetylcholine availability in myasthenia gravis a disorder characterized by muscle weakness. In both cases the relationship between VAChT and ChAT is important as ChAT levels often change in parallel affecting overall cholinergic signaling and response.\u003c\/p\u003e","brand":"Abcam","offers":[{"title":"Default Title","offer_id":46855943553193,"sku":"ab271111","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/products\/abcam-ab271111","provider":"Iright","version":"1.0","type":"link"}